RE: NEWS OUTA Class 1 Review is for a period of 3 months. A Class 2 Review is for a period of 6 months, and usually is for resolving the final labeling of the drug.
Everything appears to very positive regarding Kiacta.
"We look forward to further productive interactions with the FDA as we enter late-stage discussions on our marketing application," said Dr. Francesco Bellini, Neurochem Inc.'s Chairman, President and CEO.
As you see, Bellini states the the discussions are concerning marketing Kiacta.